<DOC>
	<DOCNO>NCT02639546</DOCNO>
	<brief_summary>This open-label , dose-escalation study design evaluate safety , tolerability , pharmacokinetics , preliminary efficacy cobimetinib pediatric young adult participant solid tumor know potential kinase pathway activation standard therapy proven ineffective intolerable curative standard-of-care treatment option exist . The study conduct two stage : dose-escalation stage expansion stage recommend dose .</brief_summary>
	<brief_title>iMATRIXcobi : Safety Pharmacokinetics Cobimetinib Pediatric Young Adult Patients With Previously Treated Solid Tumors</brief_title>
	<detailed_description />
	<criteria>For doseescalation stage : age study entry great ( &gt; ) 6 year less ( &lt; ) 18 year weigh &gt; = 20 kilogram For expansion stage : age study entry &gt; 6 year &lt; 30 year Histologically cytologically confirm tumor prior treatment proven ineffective intolerable standard therapy exist Tumor known expect RAS/RAF/MEK/ERK pathway involvement . Diagnosis MUST one follow tumor type : Central nervous system glioma , include high lowgrade glioma , DIPG Embryonal rhabdomyosarcoma nonrhabdomyosarcoma soft tissue sarcoma Neuroblastoma Melanoma Malignant peripheral nerve sheath tumor Rhabdoid tumor , include ATRT NF1associated tumor ( include plexiform neurofibroma ) , schwannoma , RASopathyassociated tumor judgment investigator life threatening , result severe symptom ( include severe pain ) , close proximity vital structure ; Measurable disease define International Neuroblastoma Response Criteria , Response Assessment NeuroOncology Criteria , Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 , evaluable nuclear medicine technique , immunocytochemistry , tumor marker reliable measure Availability tumor tissue study enrollment Lansky performance status Karnofsky performance status least 50 percent Life expectancy least 3 month Adequate hematologic , cardiac , endorgan function Body weight must great equal 20 kg Pregnant lactate woman Close proximity time treatment high dose chemotherapy , differentiation therapy , immunotherapy , autologous stem cell transplant , radiotherapy , hormonal therapy , hematopoietic growth factor , investigational therapy accord protocoldefined criterion prior initiation study drug Inability swallow tablet Impaired gastrointestinal absorption History evidence retinal pathology accord protocoldefined criterion , include serous retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>